Spyre Therapeutics falls 13.6% after $350.0 million stock offering announcement

What happened

Spyre Therapeutics (SYRE) fell 13.6% to close at $80.11 on October 6, 2026, after it announced a public offering of common stock priced at $350.0 million, according to GlobeNewsWire. The stock opened 0.7% below the prior close and traded on volume 3.3 times its 20-day average. The move came after the offering disclosure and was a large, mostly company-specific move: the stock moved far more than the market and its sector.

How big was the move

The decline was 3.5 times a typical daily move for this stock and contrasted with broader market action, as the S&P 500 rose 0.6% on the day. The Healthcare sector median fell 1.8%, leaving the stock 11.8 percentage points worse than the sector median. Over the last five sessions the stock fell 5.4%, while the S&P 500 rose 1.9% over the same period. Trading volume at 3.3 times its 20-day average underscored the unusual, company-specific nature of the session and the market's focus on the capital raise.

The technical picture

The stock sat 10.1% below its 20-day moving average and 16.0% below its 50-day moving average, while remaining 17.5% above its 200-day average. The 50-day average was above the 200-day average, a sign of an established uptrend, and the shares had spent 250 consecutive trading days above the 200-day average. The Relative Strength Index (14 days) stood at 34, in a neutral range between 30 and 70. The shares were 27.3% below the 52-week high.

Price momentum had weakened recently: over one month the stock fell 10.0% and over three months it fell 16.0%, though the one-year change remained positive at rose 404.2%, which was 387.7 percentage points ahead of the S&P 500. Volatility was 62% annualized over 60 days, lower than 79% of its own readings over five years, suggesting the recent move was large relative to the company’s shorter-term trading patterns.

Fundamentals and valuation

For the four quarters through June 30, 2026, Spyre reported revenue of $90.5 million and diluted earnings per share of $-1.95. Gross margin was 0.0% and operating margin was 222.5%. Free-cash-flow margin stood at 230.9% and return on invested capital was 18.1%. The balance sheet showed net cash of $162.0 million.

Share count over one year increased by 39.6%, a change that can dilute per-share metrics and helps explain some market sensitivity to the offering. The company’s free-cash-flow yield was 2.6%, and its market value was $8.09 billion.

Earnings and analyst expectations

Spyre’s last reported results came on August 4, 2026, when earnings per share were $-0.36 against $-0.76 expected, 52.6% above estimates. That beat marked the first of consecutive quarters beating estimates, and the average surprise over the last four reports was 28.7% above estimates. The stock’s typical two-day reaction after recent reports was it rose 3.3%.

Analysts maintained a consensus price target of $111.82, which was 39.6% above the closing price on October 6, 2026, based on 13 analysts. Ninety-two percent of those ratings were Buy and the consensus rating was Buy. The next report was scheduled for November 3, 2026.

What to watch

• November 3, 2026: next earnings report date.
• The size and timing of any further equity sales following the $350.0 million offering disclosure reported by GlobeNewsWire.
• Share count over one year increased by 39.6%, which may affect per-share metrics in upcoming reports.
• Trading volume relative to its 20-day average and any follow-through price action in the days after the offering announcement.
• Management commentary on use of proceeds and any guidance revisions at the next report.